Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capeserod - Entero Therapeutics

Next Previous
X
Search
Drug Profile

Capeserod - Entero Therapeutics

Alternative Names: SL-65.0155; SL-650155

Latest Information Update: 29 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Entero Therapeutics; sanofi-aventis
  • Class Anti-inflammatories; Antidementias; Urologics
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastroparesis
  • Preclinical Ulcerative colitis
  • Discontinued Alzheimer's disease; Urinary incontinence

Most Recent Events

  • 17 Jul 2024 Phase-I clinical trials in Gastroparesis in USA (unspecified route) (Entero Therapeutics pipeline, July 2024)
  • 16 May 2024 First Wave Biopharma is now called Entero Therapeutics
  • 05 Apr 2024 First Wave Biopharma plans a meeting with the US FDA to establish a development and regulatory pathway for Capeserod in Gastrointestinal disorders with the intent to initiate clinical trials in 2025 (First Wave BioPharma SEC 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top